Citations

Clear

9 citation(s) found for "As, Nicholas van".

P-1017. Initial Results From a Real-World Patient Registry Study of Adults Receiving Fecal Microbiota, Live-jslm for the Prevention of Recurrent Clostridioides difficile Infection: The RebyOtA Prospective Registry (ROAR)
Hise, Nicholas W Van, Reveles, Kelly R. , Khanna, Sahil , Nielsen, Lasse, Urban, Lorien E., Hise, Nicholas W. Van, Chopra, Teena , Khanna, Sahil

Mayo Clinic

Open Forum Infectious Diseases | January 12, 2026 | Volume: 13 | Issue: Supplement_1 | Pages: No page available

10.1093/ofid/ofaf695.1213 Get It

Abstract Background Fecal microbiota, live-jslm (RBL) is FDA-approved for prevention of recurrent Clostridioides difficile infection (rCDI) in adults following completion of antibiotic treatment. The safety and efficacy of RBL have been demonstrated in trials, but few studies have evaluated outcomes in real-world populations. The primary objective of ROAR (NCT05835219) is to assess RBL effectiveness in reducing rCDI through 8 weeks in clinical practice. Table 1. Treatment success rates by subgroup Methods ROAR is an ongoing, prospective, multicenter, open-label, non-interventional registry of patients receiving RBL for rCDI prevention in the United States. Adults who completed antibiotics for rCDI and are not in an interventional trial are eligible. The primary endpoint assesses the proportion of patients who experience treatment success (no CDI recurrence through 8 weeks). Other objectives describe rCDI management in real-world clinical practice and adverse events (AEs) after RBL administration. This analysis includes patients who received RBL within 30 days of completing antibiotics for rCDI. Results As of September 18, 2024, 76 patients received RBL within 30 days of completing antibiotics and completed 8 weeks of follow-up. Patients were mostly White (93.4%) and female (76.3%), with a median age of 69 years (range, 19-96 years) and a median body mass index of 24.4 (range, 16.5-49.4). Through 8 weeks, 82.9% of patients (63/76; 95% CI, 72.5%-90.6%) experienced treatment success. Similarly, the rate of treatment success was 87.8% (36/41) in the subgroup of patients who received RBL after an antibiotic washout period > 72 hours. Treatment success rates ranged from 77-100% across patient subgroups, including those stratified by age and number of previous CDI episodes within the past 3 years (Table). Overall, 18 (23.7%) patients experienced an AE, 6 (7.9%) experienced a serious AE, and 1 (1.3%) experienced an AE of special interest (large bowel obstruction). AEs assessed as related to RBL occurred in 3 patients (3.9%). There was 1 fatal AE during the study, considered unrelated to RBL. Conclusion Initial results from ROAR are consistent with previous RBL trial results, indicating that RBL is effective and safe for preventing rCDI through 8 weeks after administration in real-world practice. Disclosures Nicholas W. Van Hise, PharmD, Ferring: Advisor/Consultant|Ferring: Grant/Research Support|Innoviva: Advisor/Consultant Teena Chopra, MD, MPH, Cepheid: Advisor/Consultant|Ferring Pharmaceuticals, Inc: Advisor/Consultant|Melinta: Speaker|Pfizer: Advisor/Consultant|Pfizer: Speaker|Shinogi: Speaker Kelly R. Reveles, PharmD, PhD, AstraZeneca: Advisor/Consultant|Ferring Pharmaceuticals: Advisor/Consultant Sahil Khanna, MBBS, MS, Ferring Pharmaceuticals, Inc: Grant/Research Support|ProbioTech Inc: Advisor/Consultant|Rise: Advisor/Consultant|Takeda: Advisor/Consultant|Vedanta: Grant/Research Support Lasse Nielsen, MS, Ferring: Employee Lorien E. Urban, PhD, Ferring Pharmaceuticals Inc: Employee
The contemporary management of prostate cancer
Chakrabarti, Deep , Albertsen, Peter C. , Adkins, Aidan, Kishan, Amar U. , Murthy, Vedang, Parker, Chris, Pathmanathan, Angela, Reid, Alison , Sartor, Oliver, Walz, Jochen , Tree, Alison , Walz, Jochen , Tree, Alison C , As, Nicholas van

Mayo Clinic

CA: A Cancer Journal for Clinicians | June 27, 2025 | Volume: 75 | Issue: 6 | Pages: 552-586

10.3322/caac.70020 | PMID 40572035 Get It

Abstract Prostate cancer is the most common cancer in two thirds of the world, with an expected doubling in both incidence and mortality in the next two decades. No strong environmental associations exist for the development of prostate cancer; therefore, lifestyle measures are unlikely to mitigate this increasing burden. The last three decades have seen rapid developments in the diagnostic and therapeutic landscape of prostate cancer, including multiparametric magnetic resonance imaging, positron emission tomography, robotic surgery, image‐guided hypofractionated and stereotactic radiotherapy, novel anti‐androgens and radioligand therapies. Prostate cancer is unique in that not everyone with a diagnosis needs treatment, and active surveillance is the preferred option for some. This review discusses the contemporary management of all stages of prostate cancer in the light of these modern developments, enabling holistic individualization of treatment, and describes the promise of future research to further improve outcomes.
PUNCH CD3-OLS: A Phase 3 Prospective Observational Cohort Study to Evaluate the Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA) in Adults With Recurrent Clostridioides difficile Infection
Feuerstadt, Paul , Knapple, W , Hise, Nicholas W. Van, Baggott, Brian, Guthmueller, Beth, Bancke, Lindy, Gamborg, Michael, Steiner, Theodore S. , Handel, Daniel Van, Khanna, Sahil , Khanna, S , Feuerstadt, Paul , Chopra, Teena , Dubberke, Erik R.

Mayo Clinic

Clinical Infectious Diseases | August 23, 2024 | Volume: 80 | Issue: 1 | Pages: 43-51

10.1093/cid/ciae437 | PMID 39180326 Get It

Abstract Background The aim of this study was to evaluate the safety and efficacy of fecal microbiota, live-jslm (RBL; REBYOTA)—the first single-dose, broad consortia microbiota-based live biotherapeutic approved by the US Food and Drug Administration for preventing recurrent Clostridioides difficile infection (rCDI) in adults following standard-of-care (SOC) antibiotic treatment. Methods PUNCH CD3-OLS was a prospective, phase 3, open-label study, conducted across the US and Canada. Participants were aged ≥18 years with documented rCDI and confirmed use of SOC antibiotics. Participants with comorbidities including inflammatory bowel disease and mild-to-moderate immunocompromising conditions could be enrolled. A single dose of RBL was rectally administered within 24–72 hours of antibiotic completion. The primary endpoint was the number of participants with RBL- or administration-related treatment-emergent adverse events (TEAEs). Secondary endpoints included treatment success and sustained clinical response, at 8 weeks and 6 months after RBL administration, respectively. Results Overall, 793 participants were enrolled, of whom 697 received RBL. TEAEs through 8 weeks after administration were reported by 47.3% of participants; most events were mild or moderate gastrointestinal disorders. Serious TEAEs were reported by 3.9% of participants. The treatment success rate at 8 weeks was 73.8%; in participants who achieved treatment success, the sustained clinical response rate at 6 months was 91.0%. Safety and efficacy rates were similar across demographic and baseline characteristic subgroups. Conclusions RBL was safe and efficacious in participants with rCDI and common comorbidities. This is the largest microbiota-based live biotherapeutic study to date, and findings support use of RBL to prevent rCDI in a broad patient population. Clinical Trials Registration NCT03931941.
S145 Week 24 Efficacy and Safety Data from PRISM3: A Randomized, Placebo-Controlled Trial Evaluating CP101, an Investigational Orally Administered Microbiome Therapeutic for the Prevention of Recurrent C. difficile Infection
Allegretti, Jessica R. , Kelly, Colleen , Louie, Thomas , Fisher, Monika, Hota, Susy , Misra, Bharat , Hise, Nicholas W. Van, Yen, Eugene F. , Facg, Bullock, Jeff S., Pullman, John, Nathan, Richard, Silverman, Michael , Davis, Ian, Khanna, Sahil , Pardi, Darrell S. , Orenstein, Robert , Grinspan, Ari , El‐Nachef, Najwa , Kraft, Colleen S., Budree, Shrish , Kassam, Zain , Bullock, Jeff S., Davis, Ian, McGill, Sarah , Kraft, Colleen S. , Borody, Thomas Julius

Mayo Clinic

American Journal of Gastroenterology | October 24, 2021 | Volume: 116 | Issue: 1 | Pages: S63-S64

10.14309/01.ajg.0000773052.38150.f9 Get It

S144 CP101 Engraftment Drives Efficacy: Results From a Randomized, Placebo-Controlled Trial Evaluating CP101, an Investigational Orally Administered Microbiome Therapeutic for Prevention of Recurrent C. difficile Infection
Allegretti, Jessica R. , Kelly, Colleen , Louie, Thomas , Fisher, Monika, Hota, Susy , Misra, Bharat , Hise, Nicholas W. Van, Yen, Eugene F. , Bullock, Jeff S., Pullman, John, Nathan, Richard, Silverman, Michael , Davis, Ian, Gerardin, Ylaine, Silva, Josh, Khanna, Sahil , Pardi, Darrell S. , Orenstein, Robert , Grinspan, Ari , El‐Nachef, Najwa , Budree, Shrish , Kassam, Zain , Bullock, Jeff S., Davis, Ian, McGill, Sarah , Kraft, Colleen S. , Borody, Thomas Julius

Mayo Clinic

American Journal of Gastroenterology | October 24, 2021 | Volume: 116 | Issue: 1 | Pages: S63-S63

10.14309/01.ajg.0000773048.24890.7e Get It

S131 CP101, an Investigational Orally Administered Microbiome Therapeutic, Increases Intestinal Microbiome Diversity and Prevents Recurrent C. difficile Infection: Results From a Randomized, Placebo-Controlled Trial
Khanna, Sahil , Kelly, Colleen , Louie, Thomas , Fisher, Monika, Hota, Susy , Misra, Bharat , Hise, Nicholas W. Van, Yen, Eugene F. , Bullock, Jeff S., Pullman, John, Nathan, Richard, Silverman, Michael , Davis, Ian, Gerardin, Ylaine, Silva, Josh, Pardi, Darrell S. , Orenstein, Robert , Grinspan, Ari , El‐Nachef, Najwa , Budree, Shrish , Kassam, Zain , Allegretti, Jessica R. , Bullock, Jeff S., Davis, Ian, McGill, Sarah , Kraft, Colleen S. , Borody, Thomas Julius

Mayo Clinic

American Journal of Gastroenterology | October 24, 2021 | Volume: 116 | Issue: 1 | Pages: S57-S57

10.14309/01.ajg.0000772996.83378.7c Get It

Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes
Collaborative, The Beyond TME, Antoniou, Anthony , Beynon, John, Bhangu, Aneel , Bose, Pradeep, Boyle, Kirsten, Branagan, Graham , Burling, David , Chang, George J. , Clark, Susan K. , Colquhoun, Patrick, Crane, Christopher H. , Darzi, Ara , Das, Prajnan , Delaney, Conor P. , Desai, Anant, Davies, Mark, Dozois, Eric J. , Fitzgerald, J.E.F. , Frizelle, Frank , George, Bruce , George, Mark, Georgiou, Panagiotis , Gupta, Arun , Harris, Dean , Hawkins, M. , Holm, Torbjörn, Hompes, Roel , Jeys, Lee , Jenkins, John T. , Kiran, Ravi P. , Koh, Cherry , Laurberg, Søren , Law, Wai Lun, Liberman, A. Sender , McArthur, D. Ray, Mirnezami, Alex H. , Moran, Brendan , Mortenson, Neil, Myers, Eddie, Nicholls, R. John, O’Connell, P. R. , O’Dwyer, Sarah , Oliver, Alex, Pallan, Arvind, Patel, Prashant , Patel, Uday , Radley, Simon, Ramsey, Kelvin , Rasmussen, P., Richard, Carole, Rutten, H.J.T. , Sagar, P. M. , Sebag‐Montefiore, David , Stocchi, Luca , Swallow, Carol J. , Tait, Diana , Tan, Emile , Tekkis, Paris, As, Nicholas van , Vuong, T. , Wiggers, Theo , Wilson, Malcolm , Winter, Desmond C. , Woodhouse, Christopher, Collaborative, The Beyond TME, Ali, Simak , Brown, Gina , Wilt, Johannes H.W. de , Desai, Anant , Dietz, David , Duff, Michael J. B. , Dziki, Adam Janusz , Glynne‐Jones, Rob , Goldin, Robert , Harji, Deena Pravin , Heriot, Alexander G. , Marshall, Michelle Berger , Radley, Simon, Solomon, Michael J. , Jeys, Lee M

Mayo Clinic

British Journal of Surgery | June 21, 2013 | Volume: 100 | Issue: 8 | Pages: E1-E33

10.1002/bjs.9192_1 | PMID 23901427 Get It

Consensus abstract Background The management of primary rectal cancer beyond total mesorectal excision planes (PRC-bTME) and recurrent rectal cancer (RRC) is challenging. There is global variation in standards and no guidelines exist. To achieve cure most patients require extended, multivisceral, exenterative surgery, beyond conventional total mesorectal excision planes. The aim of the Beyond TME Group was to achieve consensus on the definitions and principles of management, and to identify areas of research priority. Methods Delphi methodology was used to achieve consensus. The Group consisted of invited experts from surgery, radiology, oncology and pathology. The process included two international dedicated discussion conferences, formal feedback, three rounds of editing and two rounds of anonymized web-based voting. Consensus was achieved with more than 80 per cent agreement; less than 80 per cent agreement indicated low consensus. During conferences held in September 2011 and March 2012, open discussion took place on areas in which there is a low level of consensus. Results The final consensus document included 51 voted statements, making recommendations on ten key areas of PRC-bTME and RRC. Consensus agreement was achieved on the recommendations of 49 statements, with 34 achieving consensus in over 95 per cent. The lowest level of consensus obtained was 76 per cent. There was clear identification of the need for referral to a specialist multidisciplinary team for diagnosis, assessment and further management. Conclusion The consensus process has provided guidance for the management of patients with PRC-bTME or RRC, taking into account global variations in surgical techniques and technology. It has further identified areas of research priority.
Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes
Collaborative, The Beyond TME, Antoniou, Anthony , Beynon, John, Bose, Pradeep, Boyle, Kirsten, Branagan, Graham , Brown, Gina , Burling, David , Chang, George J. , Clark, Susan K. , Colquhoun, Patrick, Crane, Christopher H. , Darzi, Ara , Das, Prajnan , Wilt, Johannes H. W. de, Delaney, Conor P. , Desai, Anant, Davies, Mark, Dozois, Eric J. , Fitzgerald, J.E.F. , Frizelle, Frank , George, Bruce , George, Mark, Georgiou, Panagiotis , Glynne‐Jones, R., Goldin, Robert , Gupta, Arun , Harris, Dean , Hawkins, M. , Holm, Torbjörn, Jenkins, John T. , Kiran, Ravi P. , Laurberg, Søren , Law, Wai Lun, Liberman, A. Sender , McArthur, D. Ray, Mirnezami, Alex H. , Moran, Brendan , Mortenson, Neil, Myers, Eddie, Nicholls, R. John, O’Connell, P. R. , O’Dwyer, Sarah , Oliver, Alex, Pallan, Arvind, Patel, Prashant , Radley, Simon, Ramsey, Kelvin , Rasmussen, P., Richard, Carole, Rutten, H.J.T. , Sagar, P. M. , Sebag‐Montefiore, David , Solomon, Michael J. , Stocchi, Luca , Swallow, Carol J. , Tait, Diana , Tekkis, Paris, As, Nicholas van , Vuong, T. , Wiggers, Theo , Wilson, Malcolm , Winter, Desmond C. , Woodhouse, Christopher, Coombes, R. Charles , Collaborative, The Beyond TME, Ali, Simak , Bhangu, Aneel , Desai, Anant , Dietz, David , Duff, Michael J. B. , Dziki, Adam Janusz , Harji, Deena Pravin , Heriot, Alexander G. , Hompes, Roel , Jeys, Lee , Koh, Cherry , Marshall, Michelle Berger , Patel, Uday , Radley, Simon, Tan, Emile , Solomon, Michael J

Mayo Clinic

British Journal of Surgery | June 10, 2013 | Volume: 100 | Issue: 8 | Pages: 1009-1014

10.1002/bjs.9192 | PMID 23754654 Get It

Consensus abstract Background The management of primary rectal cancer beyond total mesorectal excision planes (PRC-bTME) and recurrent rectal cancer (RRC) is challenging. There is global variation in standards and no guidelines exist. To achieve cure most patients require extended, multivisceral, exenterative surgery, beyond conventional total mesorectal excision planes. The aim of the Beyond TME Group was to achieve consensus on the definitions and principles of management, and to identify areas of research priority. Methods Delphi methodology was used to achieve consensus. The Group consisted of invited experts from surgery, radiology, oncology and pathology. The process included two international dedicated discussion conferences, formal feedback, three rounds of editing and two rounds of anonymized web-based voting. Consensus was achieved with more than 80 per cent agreement; less than 80 per cent agreement indicated low consensus. During conferences held in September 2011 and March 2012, open discussion took place on areas in which there is a low level of consensus. Results The final consensus document included 51 voted statements, making recommendations on ten key areas of PRC-bTME and RRC. Consensus agreement was achieved on the recommendations of 49 statements, with 34 achieving consensus in over 95 per cent. The lowest level of consensus obtained was 76 per cent. There was clear identification of the need for referral to a specialist multidisciplinary team for diagnosis, assessment and further management. Conclusion The consensus process has provided guidance for the management of patients with PRC-bTME or RRC, taking into account global variations in surgical techniques and technology. It has further identified areas of research priority.
Coordination of Centrosome Homeostasis and DNA Repair Is Intact in MCF-7 and Disrupted in MDA-MB 231 Breast Cancer Cells
Acu, Ilie D., Liu, Tieju , Suino-Powell, Kelly, Mooney, Steven M. , D’Assoro, Antonino B. , Correa, Ricardo G. , Niu, Yun , Kumar, Rajiv , Salisbury, Jeffrey L., Rowland, Nicholas James , Muotri, Alysson Renato , Kumar, Rajiv

Mayo Clinic

Cancer Research | April 13, 2010 | Volume: 70 | Issue: 8 | Pages: 3320-3328

10.1158/0008-5472.can-09-3800 | PMID 20388771 Get It

Abstract When cells encounter substantial DNA damage, critical cell cycle events are halted while DNA repair mechanisms are activated to restore genome integrity. Genomic integrity also depends on proper assembly and function of the bipolar mitotic spindle, which is required for equal chromosome segregation. Failure to execute either of these processes leads to genomic instability, aging, and cancer. Here, we show that following DNA damage in the breast cancer cell line MCF-7, the centrosome protein centrin2 moves from the cytoplasm and accumulates in the nucleus in a xeroderma pigmentosum complementation group C protein (XPC)–dependent manner, reducing the available cytoplasmic pool of this key centriole protein and preventing centrosome amplification. MDA-MB 231 cells do not express XPC and fail to move centrin into the nucleus following DNA damage. Reintroduction of XPC expression in MDA-MB 231 cells rescues nuclear centrin2 sequestration and reestablishes control against centrosome amplification, regardless of mutant p53 status. Importantly, the capacity to repair DNA damage was also dependent on the availability of centrin2 in the nucleus. These observations show that centrin and XPC cooperate in a reciprocal mechanism to coordinate centrosome homeostasis and DNA repair and suggest that this process may provide a tractable target to develop treatments to slow progression of cancer and aging. Cancer Res; 70(8); 3320–8. ©2010 AACR.